The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.
- Scientific resource
- Scientific publication
- Press release
- Press coverage
OncoTAM, a comprehensive preclinical platform to explore macrophages
OncoTAM targets Tumor Associated Macrophages to develop new Anticancer Therapies in a form of a comprehensive preclinical platform. Learn more here
Simultaneous 18F-FDG PET / MR imaging for metastases identification in a disseminated human preclinical melanoma model
Simultaneous 18F-FDG PET / MR imaging for metastases identification in a disseminated human preclinical Melanoma Model. Learn more here
Antitumor activity comparison of two somatostatin receptor ligands radiolabeled with Lutetium-177 (SSO110 and DOTA-TATE)
Somatostatin Receptor ligands Antitumor Activity comparison radiolabeled with Lutetium 177 alone or combined with chemotherapy in mice. Learn more here
AACR Annual Meeting 2023
The AACR Annual Meeting brings together scientists, clinicians, and other professionals to share the latest advances in cancer science. Learn more here
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases
New study investigates Pharmacological Inhibitors of DYRK and CLK Protein Kinases and their comparative efficacy and selectivity. Learn more here
IBD Case study
Discover an example of a screening cascade developed by Oncodesign Services that led to the identification of preclinical candidates.
Oncodesign Services Events in March 2023
Oncodesign is taking part in many events this March. Here is a short selection of where we are travelling over the next few weeks. Learn more here
The International Day of Women and Girls in Science
We met with women employees of Oncodesign Services to talk their careers and their ambitions for a better valorization of women in Science. Learn more here
Why preclinical cancer models still fails in the clinic?
We at Oncodesign Services strive to develop alternative Preclinical Cancer Models to better suit your drug development. Read more about our solutions here.
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
Liposomal Irinotecan is hypothesized to have a higher therapeutic index than its non-liposomal counterpart in mice with Pancreatic Cancer. Read more here.